Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors
The present invention relates to novel compounds of formula (I), methods, and compositions capable of decreasing HIF hydroxylase activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF).
1. A compound of formula I:
wherein:
q is 0, 1, 2, 3, or 4;
R 1 is hydroxyl;
R 2 is hydrogen;
R 3 is selected from the group consisting of hydrogen, deuterium, alkyl, and substituted alkyl;
R 4 is selected from the group consisting of hydrogen, deuterium, and methyl; and
each R 5 is independently selected from the group consisting of hydrogen, hydroxy, cyano, halo, nitro, acyl, amino, substituted amino, acylamino, sulfonyl, substituted sulfonyl, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, cycloalkyloxy, substituted cycloalkyloxy, heterocyclyloxy, substituted heterocyclyloxy, aryl, substituted aryl, aryloxy, substituted aryloxy, heteroaryloxy, substituted heteroaryloxy, alkylthio, substituted alkylthio, cycloalkylthio, substituted cycloalkylthio, arylthio, substituted arylthio, heteroarylthio, substituted heteroarylthio, heterocyclicthio, substituted heterocyclicthio, heteroaryl, and substituted heteroaryl; or two R 5 taken together with the carbon atoms to which they are attached form an aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heterocyclic, substituted heterocyclic, heteroaryl or substituted heteroaryl;
R 10 is —NR 11 R 12 or —OR 13 ;
R 11 and R 12 are independently selected from the group consisting hydrogen, alkyl, cycloalkyl-alkylene, (C 3 -C 8 )heterocyclic, aryl, —C(O)(C 1 -C 4 )alkyl, and alkyl-(C 3 -C 8 )cycloalkylene;
or R 11 and R 12 taken together with the nitrogen to which they are attached form a 5- or 6-membered heterocyclic or substituted heterocyclic; and
R 13 is selected from the group consisting of hydrogen, a cation, and alkyl which is unsubstituted or substituted with one or more substituents independently selected from the group consisting of cycloalkyl, heterocyclic, aryl, and heteroaryl;
or a pharmaceutically acceptable salt, single stereoisomer, or mixture of stereoisomers thereof;
provided that the compound is not [(4-hydroxy-2-oxo-2H-chromene-3-carbonyl)-amino]-acetic acid.
2. A compound of formula II:
wherein
R 2 is hydrogen;
R 3 is selected from the group consisting of hydrogen, deuterium, alkyl, and substituted alkyl;
R 4 is selected from the group consisting of hydrogen, deuterium, and methyl; and
R 6 and R 9 are independently selected from the group consisting of hydrogen, halo, alkyl, alkoxy, substituted alkoxy, cycloalkyloxy, substituted cycloalkyloxy, aryl, substituted aryl, heteroaryl, and substituted heteroaryl;
R 7 and R 8 are independently selected from the group consisting of hydrogen, hydroxy, cyano, halo, nitro, acyl, amino, substituted amino, acylamino, sulfonyl, substituted sulfonyl, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, cycloalkyloxy, substituted cycloalkyloxy, heterocyclyloxy, substituted heterocyclyloxy, aryl, substituted aryl, aryloxy, substituted aryloxy, heteroaryloxy, substituted heteroaryloxy, alkylthio, substituted alkylthio, cycloalkylthio, substituted cycloalkylthio, arylthio, substituted arylthio, heteroarylthio, substituted heteroarylthio, heterocyclicthio, substituted heterocyclicthio, heteroaryl, and substituted heteroaryl;
or one of R 6 and R 7 , R 7 and R 8 , or R 8 and R 9 taken together with the carbon atoms to which they are attached optionally form an aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heterocyclic, substituted heterocyclic, heteroaryl or substituted heteroaryl;
R 10 is —NR 11 R 12 or —OR 13 ;
R 11 and R 12 are independently selected from the group consisting hydrogen, alkyl, cycloalkyl-alkylene, (C 3 -C 8 )heterocyclic, aryl, —C(O)(C 1 -C 4 )alkyl, and alkyl-(C 3 -C 8 )cycloalkylene;
or R 11 and R 12 taken together with the nitrogen to which they are attached form a 5- or 6-membered heterocyclic or substituted heterocyclic; and
R 13 is selected from the group consisting of hydrogen, a cation, and alkyl which is unsubstituted or substituted with one or more substituents independently selected from the group consisting of cycloalkyl, heterocyclic, aryl, and heteroaryl;
or a pharmaceutically acceptable salt, single stereoisomer, or mixture of stereoisomers thereof;
provided that the compound is not [(4-hydroxy-2-oxo-2H-chromene-3-carbonyl)-amino]-acetic acid.
3. The compound of claim 1 , wherein q is 1 or 2.
4. The compound of claim 1 , wherein R 4 and R 2 are hydrogen.
5. The compound of claim 1 , wherein each R 5 is independently selected from the group consisting of hydrogen, halo, alkyl, substituted alkyl, aryl, substituted aryl, alkoxy, substituted alkoxy, cycloalkyloxy, aryloxy, substituted aryloxy, heteroaryl, and substituted heteroaryl; or two R 5 taken together with the carbon atoms to which they are attached form an aryl or substituted aryl.
6. The compound of claim 1 , wherein
R 10 is —OR 13 ; and
R 13 is selected from the group consisting of hydrogen, a cation, and alkyl which is unsubstituted or substituted with one or more substituents independently selected from the group consisting of cycloalkyl, heterocyclic, aryl, and heteroaryl.
7. The compound of claim 1 , wherein
R 1 is hydroxy;
R 2 and R 4 are hydrogen;
R 3 is selected from the group consisting of hydrogen, alkyl, and substituted alkyl; and
each R 5 is independently selected from the group consisting of hydrogen, halo, alkyl, substituted alkyl, aryl, substituted aryl, alkoxy, substituted alkoxy, cycloalkyloxy, aryloxy, substituted aryloxy, heteroaryl, and substituted heteroaryl; or two R 5 taken together with the carbon atoms to which they are attached form an aryl or substituted aryl.
8. The compound of claim 1 , wherein
q is 1 or 2;
R 1 is hydroxy;
R 2 and R 4 are hydrogen;
R 3 is selected from the group consisting of hydrogen, alkyl, and substituted alkyl; and
each R 5 is independently selected from the group consisting of hydrogen, halo, alkyl, substituted alkyl, aryl, substituted aryl, alkoxy, substituted alkoxy, cycloalkyloxy, aryloxy, substituted aryloxy, heteroaryl, and substituted heteroaryl; or two R 5 taken together with the carbon atoms to which they are attached form an aryl or substituted aryl;
R 10 is —OR 13 ; wherein R 13 is hydrogen, a cation or alkyl.
9. The compound of claim 1 , wherein
q is 0;
R 1 is hydroxy;
R 2 and R 4 are hydrogen;
R 3 is selected from the group consisting of hydrogen, alkyl, and substituted alkyl; and
R 10 is —OR 13 ; wherein R 13 is hydrogen, a cation or alkyl.
10. The compound of claim 1 , wherein
q is 1 or 2;
R 1 is hydroxy;
R 2 and R 3 are hydrogen;
R 4 is selected from the group consisting of hydrogen and methyl;
each R 5 is independently selected from the group consisting of hydrogen, halo, alkyl, substituted alkyl, aryl, substituted aryl, alkoxy, substituted alkoxy, cycloalkyloxy, aryloxy, substituted aryloxy, heteroaryl, and substituted heteroaryl; or two R 5 taken together with the carbon atoms to which they are attached form an aryl or substituted aryl; and
R 10 is —OR 13 ; wherein R 13 is hydrogen, a cation or alkyl.
11. A compound selected from the group consisting of [(6-bromo-4-hydroxy-2-oxo-2H-chromene-3-carbonyl)-amino]-acetic acid; {[4-hydroxy-6-(4-methoxy-phenyl)-2-oxo-2H-chromene-3-carbonyl]-amino}-acetic acid; {[4-hydroxy-2-oxo-6-(4-phenoxy-phenyl)-2H-chromene-3-carbonyl]-amino}-acetic acid; {[4-hydroxy-2-oxo-6-(4-trifluoromethyl-phenyl)-2H-chromene-3-carbonyl]-amino}-acetic acid; [(4-hydroxy-6-methyl-2-oxo-2H-chromene-3-carbonyl)-amino]-acetic acid; [(8-Chloro-4-hydroxy-2-oxo-2H-chromene-3-carbonyl)-amino]-acetic acid; {[6-(4-benzyloxy-phenyl)-4-hydroxy-2-oxo-2H-chromene-3-carbonyl]-amino}-acetic acid; [(4-hydroxy-2-oxo-7-phenoxy-2H-chromene-3-carbonyl)-amino]-acetic acid; [(4-Hydroxy-7,8-dimethyl-2-oxo-2H-chromene-3-carbonyl)-amino]-acetic acid; {[4-hydroxy-2-oxo-7-(4-phenoxy-phenyl)-2H-chromene-3-carbonyl]-amino}-acetic acid; 2-(S)-{[4-hydroxy-2-oxo-7-(4-phenoxy-phenyl)-2H-chromene-3-carbonyl]-amino}-propionic acid; [(6,8-dichloro-4-hydroxy-2-oxo-2H-chromene-3-carbonyl)-amino]-acetic acid; [(6,8-dichloro-4-hydroxy-2-oxo-2H-chromene-3-carbonyl)-amino]-acetic acid ethyl ester; [(4-hydroxy-6,7-dimethyl-2-oxo-2H-chromene-3-carbonyl)-amino]-acetic acid; [(6-fluoro-4-hydroxy-2-oxo-2H-chromene-3-carbonyl)-amino]-acetic acid; [(7-fluoro-4-hydroxy-2-oxo-2H-chromene-3-carbonyl)-amino]-acetic acid; [(6,8-difluoro-4-hydroxy-2-oxo-2H-chromene-3-carbonyl)-amino]-acetic acid; [(6-chloro-4-hydroxy-8-methyl-2-oxo-2H-chromene-3-carbonyl)-amino]-acetic acid; [(4-hydroxy-8-methyl-2-oxo-2H-chromene-3-carbonyl)-amino]-acetic acid; {[6-chloro-4-hydroxy-8-(2-methyl-5-trifluoromethyl-2H-pyrazol-3-yl)-2-oxo-2H-chromene-3-carbonyl]-amino}-acetic acid; {[4-hydroxy-8-(2-methyl-5-trifluoromethyl-2H-pyrazol-3-yl)-2-oxo-2H-chromene-3-carbonyl]-amino}-acetic acid; [(6-chloro-4-hydroxy-2-oxo-8-pyridin-3-yl-2H-chromene-3-carbonyl)-amino]-acetic acid; [(6-chloro-4-hydroxy-2-oxo-8-phenyl-2H-chromene-3-carbonyl)-amino]-acetic acid; [(4-hydroxy-2-oxo-8-phenyl-2H-chromene-3-carbonyl)-amino]-acetic acid; [(6-chloro-4-hydroxy-2-oxo-8-thiophen-2-yl-2H-chromene-3-carbonyl)-amino]-acetic acid; [(4-hydroxy-2-oxo-6-thiophen-2-yl-2H-chromene-3-carbonyl)-amino]-acetic acid; [(6-furan-2-yl-4-hydroxy-2-oxo-2H-chromene-3-carbonyl)-amino]-acetic acid; [(4-hydroxy-2-oxo-6-pyridin-3-yl-2H-chromene-3-carbonyl)-amino]-acetic acid; [(4-hydroxy-2-oxo-6-pyridin-2-yl-2H-chromene-3-carbonyl)-amino]-acetic acid; [(4-hydroxy-2-oxo-2H-benzo[h]chromene-3-carbonyl)-amino]-acetic acid; [(4-hydroxy-2-oxo-2H-benzo[g]chromene-3-carbonyl)-amino]-acetic acid; [(1-hydroxy-3-oxo-3H-benzo[f]chromene-2-carbonyl)-amino]acetic acid; [(7,10-Dibromo-4-hydroxy-2-oxo-2H-benzo[g]chromene-3-carbonyl)-amino]acetic acid; [(4-hydroxy-7-methyl-2-oxo-2H-chromene-3-carbonyl)-amino]-acetic acid; [(7-chloro-4-hydroxy-2-oxo-2H-chromene-3-carbonyl)-amino]-acetic acid; [(4-hydroxy-6,8-diisopropyl-2-oxo-2H-chromene-3-carbonyl)-amino]-acetic acid; [(6-benzyloxy-4-hydroxy-2-oxo-2H-chromene-3-carbonyl)-amino]-acetic acid; [(6-cyclohexylmethoxy-4-hydroxy-2-oxo-2H-chromene-3-carbonyl)-amino]-acetic acid; [(6-hexyloxy-4-hydroxy-2-oxo-2H-chromene-3-carbonyl)-amino]-acetic acid; (S)-2-[(7-chloro-4-hydroxy-2-oxo-2H-chromene-3-carbonyl)-amino]-propionic acid; (S)-2-[(6-hexyloxy-4-hydroxy-2-oxo-2H-chromene-3-carbonyl)-amino]-propionic acid; (S)-2-[(6-cyclohexylmethoxy-4-hydroxy-2-oxo-2H-chromene-3-carbonyl)-amino]-propionic acid; [(4-hydroxy-6-isopropoxy-2-oxo-2H-chromene-3-carbonyl)-amino]-acetic acid; [(8-benzyloxy-4-hydroxy-2-oxo-2H-chromene-3-carbonyl)-amino]-acetic acid; [(5-benzyloxy-4-hydroxy-2-oxo-2H-chromene-3-carbonyl)-amino]-acetic acid; {[5-(4-fluoro-benzyloxy)-4-hydroxy-2-oxo-2H-chromene-3-carbonyl]-amino}-acetic acid; {[4-hydroxy-5-(4-methyl-benzyloxy)-2-oxo-2H-chromene-3-carbonyl]-amino}-acetic acid; 2-(S)-{[5-(4-fluoro-benzyloxy)-4-hydroxy-2-oxo-2H-chromene-3-carbonyl]-amino}-propionic acid; 2-(S)-{[4-hydroxy-5-(4-methyl-benzyloxy)-2-oxo-2H-chromene-3-carbonyl]-amino}-propionic acid; [(5-cyclohexyloxy-4-hydroxy-2-oxo-2H-chromene-3-carbonyl)-amino]-acetic acid; 2-(S)-[(5-cyclohexyloxy-4-hydroxy-2-oxo-2H-chromene-3-carbonyl)-amino]-propionic acid; [(7-benzyloxy-4-hydroxy-2-oxo-2H-chromene-3-carbonyl)-amino]-acetic acid; 2-(S)-[(7-benzyloxy-4-hydroxy-2-oxo-2H-chromene-3-carbonyl)-amino]-propionic acid; {[5-(3-cyclopentyl-propoxy)-4-hydroxy-2-oxo-2H-chromene-3-carbonyl]-amino}-acetic acid; 2-(S)-{[5-(3-cyclopentyl-propoxy)-4-hydroxy-2-oxo-2H-chromene-3-carbonyl]-amino}-propionic acid; [(7-cyclohexyloxy-4-hydroxy-2-oxo-2H-chromene-3-carbonyl)-amino]-acetic acid; and 2-(S)-[(7-cyclohexyloxy-4-hydroxy-2-oxo-2H-chromene-3-carbonyl)-amino]-propionic acid or a pharmaceutically acceptable salt, single stereoisomer, or mixture of stereoisomers thereof.
12. A pharmaceutical composition comprising one or more compounds of claim 1 and a pharmaceutically acceptable excipient.
13. The composition of claim 12 , further comprising at least one additional therapeutic agent selected from the group consisting of vitamin B 12 , folic acid, ferrous sulfate, recombinant human erythropoietin, and an erythropoiesis stimulating agent (ESA).
14. A method of inhibiting the activity of a HIF hydroxylase enzyme in vitro, the method comprising bringing into contact the HIF hydroxylase enzyme and an inhibitory-effective amount of a compound of formula I:
wherein:
q is 0, 1, 2, 3, or 4;
R 1 is hydroxy;
R 2 is hydrogen;
R 3 is selected from the group consisting of hydrogen, deuterium, alkyl, and substituted alkyl;
R 4 is selected from the group consisting of hydrogen, deuterium, and methyl; and
each R 5 is independently selected from the group consisting of hydrogen, hydroxy, cyano, halo, nitro, acyl, amino, substituted amino, acylamino, sulfonyl, substituted sulfonyl, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, cycloalkyloxy, substituted cycloalkyloxy, heterocyclyloxy, substituted heterocyclyloxy, aryl, substituted aryl, aryloxy, substituted aryloxy, heteroaryloxy, substituted heteroaryloxy, alkylthio, substituted alkylthio, cycloalkylthio, substituted cycloalkylthio, arylthio, substituted arylthio, heteroarylthio, substituted heteroarylthio, heterocyclicthio, substituted heterocyclicthio, heteroaryl, and substituted heteroaryl; or two R 5 taken together with the carbon atoms to which they are attached form an aryl, substituted aryl, heteroaryl or substituted heteroaryl;
R 10 is —NR 11 R 12 or —OR 13 ;
R 11 and R 12 are independently selected from the group consisting hydrogen, alkyl, cycloalkyl-alkylene, (C 3 -C 8 )heterocyclic, aryl, —C(O)(C 1 -C 4 )alkyl, and alkyl-(C 3 -C 8 )cycloalkylene;
or R 11 and R 12 taken together with the nitrogen to which they are attached form a 5- or 6-membered heterocyclic or substituted heterocyclic; and
R 13 is selected from the group consisting of hydrogen, a cation, and alkyl which is unsubstituted or substituted with one or more substituents independently selected from the group consisting of cycloalkyl, heterocyclic, aryl, and heteroaryl;
or a pharmaceutically acceptable salt, single stereoisomer, or mixture of stereoisomers thereof.
15. The method of claim 14 , wherein the HIF hydroxylase enzyme is an asparaginyl hydroxylase.
16. The method of claim 15 , wherein the asparaginyl hydroxylase is Factor inhibiting HIF (FIH).
17. The method of claim 14 , wherein the HIF hydroxylase enzyme is a prolyl hydroxylase.
18. The method of claim 17 , wherein the prolyl hydroxylase is selected from the group consisting of human EGLN1, EGLN2, and EGLN3.